Reference : Post-remission strategies for the prevention of relapse following allogeneic hematopo...
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/234315
Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
English
Lee, C. J. [Utah Blood and Marrow Transplant Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States]
Savani, B. N. [Vanderbilt University Medical Center, Nashville, TN, United States]
Mohty, M. [Department of Hematology, Hopital Saint-Antoine, APHP and University UPMC, Paris, France]
Gorin, N. C. [Department of Hematology, Hopital Saint-Antoine, APHP and University UPMC, Paris, France]
Labopin, M. [Department of Haematology, Hopital Saint-Antoine, INSERM, Paris, France]
Ruggeri, A. [Department of Haematology, Hopital Saint-Antoine, INSERM, Paris, France]
Schmid, C. [Klinikum Augsburg, Dept. of Hematology and Oncology, University of Munich, Augsburg, Germany]
Baron, Frédéric mailto [Université de Liège - ULiège > > GIGA-R : Hématologie >]
Esteve, J. [Department of Hematology, Hospital Clinic, IDIBAPS, Barcelona, Spain]
Giebel, S. [Maria Sklodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland]
Ciceri, F. [Department of Hematology, IRCCS San Raffaele Scientific Institute, Milano, Italy]
Nagler, A. [Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel, Acute Leukemia Working Party – EBMT Paris office, Hȏpital Saint-Antoine, Paris, France]
In press
Bone Marrow Transplantation
Nature Publishing Group
Yes (verified by ORBi)
International
02683369
[en] Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy generally associated with poor prognosis. Allogeneic hematopoietic cell transplantation (alloHCT) continues to be the most potent anti-leukemia treatment for adult patients with intermediate and high-risk AML. However, disease relapse after alloHCT remains unacceptably high and is the primary cause of treatment failure and mortality following alloHCT. It is therefore that post-transplant early cellular or pharmacologic maintenance or preemptive strategies to enhance the graft-versus-leukemia effect or to eradicate persistent minimal residual disease have been of renewed interest, particularly with the availability of more sensitive technologies to measure residual AML. Although preliminary studies have demonstrated improved outcomes with the use of post-alloHCT remission therapies, prospective randomized trials are required to determine their clinical efficacy and role in the treatment of AML. On behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use and efficacy of available pharmacologic post-remission therapies, including hypomethylating agents, deacetylase inhibitors, and tyrosine kinase inhibitors, as well as cellular therapies, including preemptive and prophylactic donor lymphocyte infusions for the prevention of relapse of AML. © 2018, Springer Nature Limited.
http://hdl.handle.net/2268/234315
10.1038/s41409-018-0286-2

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Lee-Post-remission strategies-BMT 2019.pdfPublisher postprint601.5 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.